Iranian company produces drug for diabetic foot ulcers, burns

An Iranian knowledge-based company has localized a drug for treating diabetic foot ulcers and burns, achieving significant foreign currency savings of approximately 25 million tomans per unit. 

According to the Center for Communications and Information of the Iranian Vice-Presidency for Science, Technology, and Knowledge-Based Economy, Fahimeh Mohammad Hosseini, the CEO of Daroo Darman Borna, announced, “For the first time in the country, we have successfully produced Barnamin epidermal growth factor. The drug is used in treating diabetic foot ulcers and third and fourth-degree burns.” 

Mohammad Hosseini highlighted the economic benefits, stating, “The foreign cost of the drug is around 300 pounds, but by localizing it, the cost for customers is approximately 25 million tomans, resulting in significant foreign currency savings.” 

She also mentioned that Barnamin is available in both injectable and topical forms. 

The topical form has reached industrial production and is available in the domestic market, while the injectable form is awaiting approval from the Food and Drug Administration. 

Daroo Darman Borna started its operations in 2014 in the field of pharmaceutical and medical biotechnology. The company focuses on producing novel drugs based on recombinant proteins and biosimilars.